DrugPatentWatch Database Preview
Details for Patent: 8,450,344
Email this page to a colleague
» See Plans and PricingWhich drugs does patent 8,450,344 protect, and when does it expire?
Patent 8,450,344 protects RHOPRESSA and ROCKLATAN and is included in two NDAs.
This patent has nine patent family members in six countries.
Summary for Patent: 8,450,344
| Title: | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| Abstract: | Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds. |
| Inventor(s): | deLong; Mitchell A. (Raleigh, NC), Sturdivant; Jill Marie (Chapel Hill, NC), Royalty; Susan M. (Cary, NC) |
| Assignee: | Aerie Pharmaceuticals, Inc. (Research Triangle Park, NC) |
| Application Number: | 12/180,259 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,450,344
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aerie Pharms Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE | Start Trial | ||
| Aerie Pharms Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,450,344
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009273932 | Start Trial | |||
| Canada | 2731869 | Start Trial | |||
| European Patent Office | 2326623 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
